Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients with H

这项研究是在两组儿童中枢神经系统肿瘤患者中进行的--弥漫性桥脑胶质瘤是一种主要发病于5-10岁儿童的致命疾病，中位生存期为1年；另一组是复发的高级别胶质瘤，预后也同样很差。这项研究分两个阶段进行。在16名患者中进行了最初的第一阶段；如果观察到客观反应，队列将扩大(第二阶段)。如果没有观察到任何反应，则将关闭该手臂的研究。我们已经达到了每个手臂第一阶段的应计目标。高级别胶质瘤队列已扩大到第二阶段。这项研究继续达到其在儿科脑瘤联盟内的应计目标。

The study is being performed in two groups of pediatric CNS tumor patients-those with diffuse intrinsic pontine glioma which is a deadly disease which primarily strikes children 5-10 years of age and has a median survival of <1 year, and recurent high-grade gliomas which also has a similarly poor prognosis. The study is being performed intwo stages. An initial first stage is performed in 16 patients; if an objective response is observed, the cohort will expand (second stage). If no responses are observed, the study for that arm will be closed. We have reached our accrual goals for the first stage of each arm. The high grade glioma cohort has been expanded to the second stage. This study continues to meet its accrual goals within the Pediatric Brain Tumor Consortium.